Australia markets close in 3 hours 45 minutes

Medtronic plc (MDT)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
118.26+2.99 (+2.59%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close115.27
Open115.71
Bid117.02 x 1200
Ask118.91 x 900
Day's range115.26 - 118.76
52-week range72.13 - 120.53
Volume4,636,133
Avg. volume4,462,093
Market cap159.352B
Beta (5Y monthly)0.74
PE ratio (TTM)52.35
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield2.32 (1.96%)
Ex-dividend date21 Dec 2020
1y target estN/A
All
News
Press releases
  • Medtronic Announces First Procedures in Pivotal Trial to Evaluate Novel Ablation Technology in Treating Atrial Fibrillation
    PR Newswire

    Medtronic Announces First Procedures in Pivotal Trial to Evaluate Novel Ablation Technology in Treating Atrial Fibrillation

    Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the first procedures in the investigational device exemption (IDE) pivotal trial to evaluate the PulseSelect™ Pulsed Field Ablation (PFA) System, a novel, breakthrough technology that uses pulsed electric fields to treat atrial fibrillation (AF). The first procedure in the PULSED AF pivotal trial was performed this week at Southcoast Health by Nitesh Sood, M.D., Fall River, Massachusetts; the second procedure was performed by Arnoldas Giedrimas, M.D., also at Southcoast Health. The PULSED AF Trial is the first global, pre-market, multi-center clinical study with IDE approval aimed to establish the safety and efficacy of the PulseSelect System.

  • New Analysis of REVERSE Trial Reveals Benefits of CRT for More Patients with Heart Failure
    PR Newswire

    New Analysis of REVERSE Trial Reveals Benefits of CRT for More Patients with Heart Failure

    Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac resynchronization therapy (CRT) for patients with mild heart failure (HF). This new analysis of the REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) clinical trial shows that patients whose heart failure stabilizes with CRT live longer, similar to patients whose condition improves with CRT. The manuscript was recently published in the Journal of American College of Cardiology: Clinical Electrophysiology.

  • Medtronic Reports Third Quarter Fiscal 2021 Financial Results
    PR Newswire

    Medtronic Reports Third Quarter Fiscal 2021 Financial Results

    Medtronic plc (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2021, which ended January 29, 2021.